posted
ThermoGenesis Announces Launch of Res-Q System; New Device Expands Company's Presence in Bone Marrow Sector Thursday 08/06/2009 4:10 PM ET - Pr Newswire
Related Companies Symbol Last %Chg KOOL 0.66 4.76%
As of 12:33 PM ET 8/7/09 ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products for processing and storing adult stem cells, announced today the introduction of the Res-Q(TM) 60 BMC ("Res-Q") System, an automated cell processing medical device for the concentration of bone marrow-derived stem cells at the point of care.
The Res-Q System processes bone marrow in minutes and delivers a high rate of stem cell recovery. The Res-Q System follows the late 2008 launch of the MXP(TM) MarrowXpress(TM) ("MXP") System, a laboratory device also used to collect stem cells from bone marrow.
The Company plans to initially target the orthopedic regenerative medicine market through its orthopedic distribution partner Celling Technologies ("Celling"), a subsidiary of SpineSmith, LLC. Celling is a leading distributor of orthopedic products based in Texas and also serves as a distributor of the MXP System. In a separate press release today, ThermoGenesis and Celling announced an expanded collaboration between the two firms. Separately, the Company plans to expand Res-Q's applications into the cardiovascular and other non-orthopedic regenerative medicine markets.
"We are excited to add a new member to our stem cell processing product family to help us access the growing regenerative medicine market in a meaningful way. We believe our Res-Q System has considerable advantages over competing products and should help surgeons realize the true value of autologous cellular therapy," said J. Melville Engle, Chief Executive Officer of ThermoGenesis.
"We are delighted to be participating in the launch of the Res-Q System with ThermoGenesis," said Kevin Dunworth, Chief Executive Officer of SpineSmith, LLC. "The device represents a high level of innovative technology and we look forward to building upon our early success with the MXP," he added.
About ThermoGenesis Corp.
ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These products include:
posted
Yes, got this one about the same time I bought OPXA, more news just a sec ago, Give me Volume!!!!
ThermoGenesis expands collaboration with Celling Technologies 9 minutes ago - Datamonitor
Related Companies Symbol Last %Chg KOOL 0.67 6.35%
As of 1:23 PM ET 8/7/09 ThermoGenesis, a developer of automated blood processing systems and disposable products, has expanded collaboration with Celling Technologies, a distributor of orthopedic products, related to the company's bone marrow products, MXP MarrowXpress and Res-Q 60 BMC.
As part of this expanded collaboration, ThermoGenesis and Celling will share in the funding for clinical studies to demonstrate the clinical effectiveness of both the MXP and Res-Q systems with Celling's orthopedic applications.
Incremental funding for clinical studies will be provided by ThermoGenesis and Celling as MXP and Res-Q sales grow. Celling will be responsible for coordinating the clinical trials.
ThermoGenesis has also launched its Res-Q system, an automated cell processing medical device for the concentration of bone marrow-derived stem cells at the point of care. Celling will be the distributor for the Res-Q System in orthopedic applications. Celling will also continue distributing the MXP system for the company.
According to ThermoGenesis, the Res-Q system is a microprocessor-controlled device and has a dedicated single-use disposable bag set for concentrating stem cells derived from bone marrow. It allows clinicians to automate blood volume reduction and facilitates cryopreservation of processed bone marrow aspirates. The bone marrow concentrates are used in spinal fusion procedures.
Melville Engle, CEO of ThermoGenesis, said: "Celling has done an excellent job of supporting the MXP and we look forward to working with them with the launch of Res-Q and with this broader collaboration agreement. We expect that positive study results will accelerate the market adoption of our bone marrow processing technologies and should increase product sales."
posted
Made some cash in 2009!! THERMOGENESIS Guides Below Estimates Thursday 08/06/2009 6:42 PM ET - Earningswhispers Earnings Guidance
Related Companies Symbol Last %Chg KOOL 0.68 7.92%
As of 1:38 PM ET 8/7/09 THERMOGENESIS Corp. (NASDAQ: KOOL) said it expects fiscal 2009 revenue of $19.5 million to $20.0 million. The current consensus estimate is revenue of $22.1 million for the year ending June 30, 2009.
This earnings guidance summary was provided by EarningsWhispers, a leading provider of earnings expectations - including corporate guidance announcements and analysts' expectations that differ from published estimates. http://www.earningswhispers.com
posted
If you also bought KOOL,depending on the price, and when you bought it. It semms to me that it will climb some. Yesterday was moving too. I would wait till next week to see what it will do, but if you think that you have made a reasonable money and based on what you paid for it, I would not be greedy because you can always buy it back after sale at a much lower price. Again it depends on what your investment plan is...maybe you want hold on to it for a long time and that may get you to where OPXA did, if not sooner. OPXA and KOOL are two different stocks and companies, therefore activities are also different. I would say wait and see it grow somemore, but do not take my word if your research and guts feelings says otherwise.
IP: Logged |
ThermoGenesis Names Harold ('Hal') Baker Vice President of Sales 43 minutes ago - Pr Newswire
Related Companies Symbol Last %Chg KOOL 0.72 5.88%
As of 3:58 PM ET 8/10/09 ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products for processing and storing adult stem cells, said today that Hal Baker has joined the Company as Vice President, Sales, effective immediately.
Mr. Baker has more than two decades of global sales and marketing experience in the healthcare sector, introducing new products, leading teams in the cord blood stem cell market, managing distributor relationships and building sales force organizations.
Most recently, Mr. Baker was Vice President, Global Sales, for Hygenic Corporation, a global manufacturer and marketer of over the counter pain relievers, rehabilitation consumables and OEM specialty products for the medical and dental markets. Before that, he was Senior Vice President, U.S. Commercial Operations, and Senior Vice President, Global Marketing, for Pall Corporation, a $2 billion filtration and separation products manufacturer serving the life science and industrial markets.
Mr. Baker spent four years as Director, Global Marketing, for Gambro Healthcare, a provider of automated blood and stem cell collection technologies. Before that, he held senior sales and marketing management positions with two medical device companies, U.S. Medical Instruments and IVAC Corporation. He holds a B.A. in Political Science from Miami University of Ohio, and a Master's in Political Science from Kent State University.
"We are fortunate to have someone of Hal's background and experience joining ThermoGenesis at this important time in the Company's development," said J. Melville Engle, Chief Executive Officer of ThermoGenesis. "Hal has a strong record of executing successful sales strategies, new product launches and market expansion initiatives, and he has extensive experience in both the cord blood and stem cell sectors.
"We have exciting opportunities, not only with our BioArchive(R) Systems and AXP(R) AutoXpress(TM) ("AXP") offerings for the cord blood market, but also with our initiatives in the bone marrow sector through our MXP(TM) MarrowXpress(TM) System ("MXP"), and the recently introduced Res-Q(TM) 60 BMC ("Res-Q") System that address the point of care market," Engle added.
Last week, ThermoGenesis announced the launch of the Res-Q System, an automated cell processing system for the concentration of bone marrow-derived stem cells at the point of care, and an expanded collaboration for the Res-Q and MXP with Celling Technologies, a subsidiary of SpineSmith, LLC, a leading distributor of orthopedic products. The MXP is a microprocessor-controlled device and a dedicated single-use disposable bag set for concentrating stem cells. The bone marrow concentrates collected by the MXP are used in spinal fusion procedures.
"I am delighted to be joining ThermoGenesis as the Company continues to progress on its turnaround strategy. I look forward to working with Mel and other members of the management team in developing and implementing an effective sales strategy and capitalizing on new market opportunities for the Company's current and future offerings," Mr. Baker said.
About ThermoGenesis Corp.
ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These products include:
-- The BioArchive(R) System, an automated cryogenic device, is used by cord blood stem cell banks in more than 25 countries for cryopreserving and archiving cord blood stem cell units for transplant. -- AXP(R) AutoXpress(TM) Platform ("AXP"), a proprietary family of automated devices that includes the AXP and the MXP(R) MarrowXpress ("MXP") and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood. GE Healthcare is the exclusive global distribution partner for the AXP cord blood product except for Central and South America, China and Russia/CIS, where ThermoGenesis markets through independent distributors. The MXP is used for isolating stem cells from bone marrow. -- The Res-Q(TM) 60 BMC ("Res-Q"), a point of care system that is designed for bone marrow stem cell processing. This product was launched in July 2009.
-- The CryoSeal(R) FS System, an automated device and companion sterile blood processing disposable, is used to prepare fibrin sealants from plasma in about an hour. The CryoSeal FS System is approved in the U.S. for liver resection surgeries. The CryoSeal FS System has received the CE-Mark which allows sales of the product throughout the European community. Asahi Medical is the exclusive distributor for the CryoSeal System in Japan and the Company markets through independent distributors in Europe and South America.
This press release contains forward-looking statements, and such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal years 2009 and 2010, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2010 and 2010. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
ThermoGenesis Corp. Web site: http://www.thermogenesis.com Contact: Investor Relations +1-916-858-5107, or ir*thermogenesis.com
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Wink]](wink.gif)
